A Phase 2 interventional study of Grazoprevir and Uprifosbuvir in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing grazoprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. grazoprevir · Hepatitis C.
Among the 18 studies testing grazoprevir in Hepatitis C, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 6 in phase 2, and was the 12th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 18 studies testing grazoprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
grazoprevir: first FDA approval 2016 (ZEPATIER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 8 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2015.
This study's enrollment of 443 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 119 across the 18 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 6 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
92 studies in Hepatitis C by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 86 finished, 66 (77%) have results posted.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one is the 5th largest by enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2015, is one of 20 in phase 2, and was the 80th registered.
Merck & Co., Inc’s Hepatitis C studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing grazoprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 92 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, three-part, open-label trial of grazoprevir (GZR; MK-5172) (100 mg) and uprifosbuvir (UPR; MK-3682) (300 mg or 450 mg), with either elbasvir (EBR; MK-8742) (50 mg) or ruzasvir (RZR; MK-8408) (60 mg), and with or without ribavirin (RBV), in treatment-naïve (TN) cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) participants with chronic HCV genotype (GT) 1 or GT2 infection. Part A will consist of 8 arms to evaluate the safety of dose combinations. In Part B, participants will take 2 UPR+GZR+RZR fixed dose combination (FDC) tablets once daily (q.d.) by mouth, with or without twice-daily (b.i.d.) RBV (200 mg capsules; weight-based dosing). Participants who relapse following completion of therapy in Part A will be offered the option of retreatment with 16 weeks of UPR+GZR+RZR with RBV in Part C (data obtained from Part C will not be used in the analysis of outcome measures).
In Part A, study therapy will be administered as separate products, each taken q.d. by mouth. In Part B and Part C, participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg q.d. by mouth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Parts A and B:
Part B only:
Exclusion Criteria:
Parts A, B, and C (unless noted otherwise):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir
In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir
In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir
In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir
In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir
In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir
In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir
In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir
In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir · Drug: Ribavirin
In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir · Drug: Ribavirin
In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
Also known as: MK-5172
Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
Also known as: MK-3682
One EBR 50 mg tablet (Part A), taken q.d. by mouth.
Also known as: MK-8742
Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
Also known as: MK-8408
Drug page: MK-3682B
Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
Also known as: MK-3682B
RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
Also known as: Rebetol®
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)
The percentage of participants with Hepatitis C virus (HCV) ribonucleic acid (RNA) \< Lower Limit of Quantification (LLoQ) 12 weeks after completing treatment (i.e., SVR12) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.
Time frame: Up to 28 weeks
Percentage of Participants Experiencing an Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 18 weeks
Percentage of Participants Discontinuing From Study Treatment Due to an AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 16 weeks
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)
The percentage of participants with HCV RNA \< LLoQ 24 weeks after completing treatment (i.e., SVR24) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.
Time frame: Up to 40 weeks
This trial was conducted at 95 study sites in Asia, the European Union, and North America.
| Milestone | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | B16: GT2 C GZR+UPR+RZR (16 Weeks) | B6: GT1 NC GZR+UPR+RZR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 23 | 24 | 16 | 14 | 23 | 23 | 15 | 16 | 48 | 31 | 31 | 35 | 40 | 15 | 16 | 26 | 30 | 16 |
| Completed | 23 | 24 | 15 | 13 | 23 | 22 | 15 | 16 | 48 | 28 | 29 | 35 | 35 | 15 | 16 | 26 | 30 | 16 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 2 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The percentage of participants with Hepatitis C virus (HCV) ribonucleic acid (RNA) \< Lower Limit of Quantification (LLoQ) 12 weeks after completing treatment (i.e., SVR12) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.
| Percentage of Participants | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | 16: GT2 C GZR+UPR+RZR (16 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12) | 100.0 (85.2 to 100.0) | 100.0 (85.8 to 100.0) | 68.8 (41.3 to 89.0) | 71.4 (41.9 to 91.6) | 100.0 (85.2 to 100.0) | 91.3 (72.0 to 98.9) | 100.0 (88.4 to 100.0) | 60.0 (32.3 to 83.7) | 93.8 (69.8 to 99.8) | 87.5 (61.7 to 98.4) | 100.0 (92.6 to 100.0) | 83.3 (65.3 to 94.4) | 100.0 (88.4 to 100.0) | 97.1 (85.1 to 99.9) | 100.0 (91.0 to 100.0) | 100.0 (78.2 to 100.0) | 100.0 (79.4 to 100.0) | 100.0 (86.3 to 100.0) |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of Participants | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | 16: GT2 C GZR+UPR+RZR (16 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing an Adverse Event (AE) | 60.9 | 83.3 | 56.3 | 71.4 | 73.9 | 60.9 | 62.3 | 86.7 | 75.0 | 68.8 | 72.9 | 80.6 | 71.0 | 57.1 | 72.5 | 53.3 | 81.3 | 69.2 |
The percentage of participants with HCV RNA \< LLoQ 24 weeks after completing treatment (i.e., SVR24) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.
| Percentage of Participants | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | 16: GT2 C GZR+UPR+RZR (16 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24) | 100.0 (85.2 to 100.0) | 100.0 (85.8 to 100.0) | 68.8 (41.3 to 89.0) | 71.4 (41.9 to 91.6) | 100.0 (85.2 to 100.0) | 90.9 (70.8 to 98.9) | 100.0 (88.4 to 100.0) | 60.0 (32.3 to 83.7) | 93.8 (69.8 to 99.8) | 87.5 (61.7 to 98.4) | 100.0 (92.6 to 100.0) | 83.3 (65.3 to 94.4) | 100.0 (88.1 to 100.0) | 97.1 (85.1 to 99.9) | 100.0 (90.1 to 100.0) | 100.0 (78.2 to 100.0) | 100.0 (79.4 to 100.0) | 100.0 (86.3 to 100.0) |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of Participants | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | 16: GT2 C GZR+UPR+RZR (16 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Discontinuing From Study Treatment Due to an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.5 | 0 | 0 | 2.5 | 0 | 12.5 | 0 |
Collected over Up to 18 weeks (14 days after completing treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A1: GT1 NC GZR+UPR+EBR (8 Weeks) | — | 0/23 (0%) | 13/23 (56.5%) |
| A2: GT1 NC GZR+UPR+RZR (8 Weeks) | — | 1/24 (4.2%) | 19/24 (79.2%) |
| A3: GT2 NC GZR+UPR+EBR (8 Weeks) | — | 1/16 (6.3%) | 10/16 (62.5%) |
| A4: GT2 NC GZR+UPR+RZR (8 Weeks) | — | 1/14 (7.1%) | 10/14 (71.4%) |
| A5: GT1 NC GZR+UPR+EBR (8 Weeks) | — | 0/23 (0%) | 15/23 (65.2%) |
| A6: GT1 NC GZR+UPR+RZR (8 Weeks) | — | 0/23 (0%) | 13/23 (56.5%) |
| A7: GT2 NC GZR+UPR+EBR (8 Weeks) | — | 0/15 (0%) | 13/15 (86.7%) |
| A8: GT2 NC GZR+UPR+RZR (8 Weeks) | — | 0/16 (0%) | 12/16 (75%) |
| B6: GT1 NC GZR+UPR+RVR (8 Weeks) | — | 0/30 (0%) | 18/30 (60%) |
| B8: GT2 NC GZR+UPR+RZR (8 Weeks) | — | 1/16 (6.3%) | 11/16 (68.8%) |
| B9: GT1 NC GZR+UPR+RZR (12 Weeks) | — | 0/48 (0%) | 35/48 (72.9%) |
| B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVMax 62 Characters... | — | 2/31 (6.5%) | 24/31 (77.4%) |
| B11: GT2 NC GZR+UPR+RZR (12 Weeks) | — | 0/31 (0%) | 19/31 (61.3%) |
| B12: GT1 C GZR+UPR+RZR (8 Weeks) | — | 1/35 (2.9%) | 19/35 (54.3%) |
| B13: GT1 C GZR+UPR+RZR (12 Weeks) | — | 3/40 (7.5%) | 26/40 (65%) |
| B14: GT2 C GZR+UPR+RZR (12 Weeks) | — | 0/15 (0%) | 8/15 (53.3%) |
| B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | — | 0/16 (0%) | 13/16 (81.3%) |
| B16: GT2 C GZR+UPR+RZR (16 Weeks) | — | 2/26 (7.7%) | 14/26 (53.8%) |
| Event | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVMax 62 Characters... | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | B16: GT2 C GZR+UPR+RZR (16 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Substance-induced psychotic disorderPsychiatric disorders | 0/23 | 0/24 | 0/16 | 1/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| TachycardiaCardiac disorders | 0/23 | 0/24 | 1/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| VomitingGastrointestinal disorders | 0/23 | 0/24 | 1/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 1/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| Retinal artery occlusionEye disorders | 0/23 | 1/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 1/26 |
| PneumoniaInfections and infestations | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 1/26 |
| OesophagitisGastrointestinal disorders | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 1/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| DepressionPsychiatric disorders | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 1/31 | 0/31 | 0/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| Pilonidal cystInfections and infestations | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 0/30 | 0/16 | 0/48 | 0/31 | 0/31 | 1/35 | 0/40 | 0/15 | 0/16 | 0/26 |
| Event | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVMax 62 Characters... | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | B16: GT2 C GZR+UPR+RZR (16 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/23 | 7/24 | 3/16 | 2/14 | 8/23 | 3/23 | 5/15 | 9/16 | 2/30 | 3/16 | 15/48 | 8/31 | 7/31 | 5/35 | 5/40 | 2/15 | 2/16 | 4/26 |
| NauseaGastrointestinal disorders | 2/23 | 3/24 | 1/16 | 2/14 | 3/23 | 0/23 | 6/15 | 3/16 | 5/30 | 2/16 | 7/48 | 5/31 | 1/31 | 1/35 | 3/40 | 2/15 | 3/16 | 4/26 |
| FatigueGeneral disorders | 4/23 | 3/24 | 2/16 | 2/14 | 6/23 | 4/23 | 6/15 | 6/16 | 4/30 | 3/16 | 8/48 | 4/31 | 1/31 | 3/35 | 3/40 | 1/15 | 5/16 | 3/26 |
| DizzinessNervous system disorders | 1/23 | 0/24 | 0/16 | 0/14 | 4/23 | 0/23 | 4/15 | 0/16 | 1/30 | 0/16 | 1/48 | 0/31 | 0/31 | 1/35 | 1/40 | 0/15 | 1/16 | 0/26 |
| DyspepsiaGastrointestinal disorders | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 3/15 | 0/16 | 0/30 | 1/16 | 0/48 | 0/31 | 1/31 | 0/35 | 1/40 | 0/15 | 1/16 | 0/26 |
| FlatulenceGastrointestinal disorders | 1/23 | 2/24 | 1/16 | 0/14 | 2/23 | 1/23 | 3/15 | 2/16 | 0/30 | 0/16 | 3/48 | 0/31 | 2/31 | 1/35 | 1/40 | 0/15 | 0/16 | 2/26 |
| NasopharyngitisInfections and infestations | 0/23 | 1/24 | 1/16 | 0/14 | 0/23 | 0/23 | 3/15 | 3/16 | 0/30 | 1/16 | 1/48 | 3/31 | 1/31 | 1/35 | 3/40 | 0/15 | 0/16 | 1/26 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/23 | 1/24 | 0/16 | 0/14 | 0/23 | 0/23 | 3/15 | 0/16 | 0/30 | 0/16 | 2/48 | 1/31 | 2/31 | 1/35 | 2/40 | 0/15 | 0/16 | 0/26 |
| PruritusSkin and subcutaneous tissue disorders | 0/23 | 1/24 | 1/16 | 0/14 | 0/23 | 2/23 | 3/15 | 0/16 | 0/30 | 0/16 | 1/48 | 5/31 | 1/31 | 0/35 | 1/40 | 0/15 | 1/16 | 0/26 |
| VomitingGastrointestinal disorders | 0/23 | 0/24 | 0/16 | 0/14 | 0/23 | 0/23 | 0/15 | 0/16 | 2/30 | 0/16 | 2/48 | 1/31 | 0/31 | 0/35 | 1/40 | 0/15 | 3/16 | 2/26 |
The Baseline Population consists of all randomized participants who received study medication.
| Age, Continuous(Years) | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | B16: GT2 C GZR+UPR+RZR (16 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 50.2 ± 13.5 | 45.0 ± 14.5 | 49.4 ± 15.8 | 52.6 ± 11.6 | 49.0 ± 11.2 | 46.7 ± 13.9 | 52.9 ± 12.1 | 48.3 ± 8.8 | 48.8 ± 13.9 | 49.8 ± 13.0 | 55.6 ± 14.4 | 58.8 ± 9.6 | 56.9 ± 11.1 | 61.8 ± 6.8 | 59.8 ± 8.0 | 64.0 ± 9.3 | 47.4 ± 11.7 | 51.4 ± 10.8 | 52.6 ± 13.0 |
| Sex: Female, Male(Participants) | A1: GT1 NC GZR+UPR+EBR (8 Weeks) | A2: GT1 NC GZR+UPR+RZR (8 Weeks) | A3: GT2 NC GZR+UPR+EBR (8 Weeks) | A4: GT2 NC GZR+UPR+RZR (8 Weeks) | A5: GT1 NC GZR+UPR+EBR (8 Weeks) | A6: GT1 NC GZR+UPR+RZR (8 Weeks) | A7: GT2 NC GZR+UPR+EBR (8 Weeks) | A8: GT2 NC GZR+UPR+RZR (8 Weeks) | B9: GT1 NC GZR+UPR+RZR (12 Weeks) | B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBV | B11: GT2 NC GZR+UPR+RZR (12 Weeks) | B12: GT1 C GZR+UPR+RZR (8 Weeks) | B13: GT1 C GZR+UPR+RZR (12 Weeks) | B14: GT2 C GZR+UPR+RZR (12 Weeks) | B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV | B16: GT2 C GZR+UPR+RZR (16 Weeks) | B6: GT1 NC GZR+UPR+RVR (8 Weeks) | B8: GT2 NC GZR+UPR+RZR (8 Weeks) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 10 | 13 | 7 | 5 | 14 | 9 | 9 | 8 | 21 | 16 | 16 | 14 | 11 | 3 | 4 | 9 | 14 | 9 | 192 |
| Male | 13 | 11 | 9 | 9 | 9 | 14 | 6 | 8 | 27 | 15 | 15 | 21 | 29 | 12 | 12 | 17 | 16 | 7 | 250 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2015 to primary completion in Sep 2016, 19 months.
Results were first posted in Dec 2017, 1 year 3 months after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 19 months is above that.
Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Grazoprevir · Uprifosbuvir · Elbasvir · Ruzasvir · MK-3682B